Incorporando los inhibidores de CDK 4/6 a la práctica Clínica habitual

30 / 38

P+ ET
N=57
P
N=58
Clinical benefit rate, n (%)
95%C.I.
31 (54%)
41.5; 63.7
35 (60%)
47.8; 72.9
CR 0 (0%) 0 (0%)
PR 6 (10%) 4 (7%)
SD ≥ 24 weeks 25 (44%) 31 (53%)
Primary endpoint: Clinical Benefit Rate
Malorni L, et al. ASCO 2017